Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 541-546

  Pielichowski, W ^a   Gawronski, K ^a   Mlot, B ^a   Oborska, S ^a   Wasko Grabowska, A ^a   Rzepecki, Piotr ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Antiemetic therapy; Hematopoietic stem cell transplantation; High dose chemotherapy; NK1 receptor antagonists; Serotonin receptor antagonists; Steroids

Indexed keywords

APREPITANT; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ONDANSETRON; PALONOSETRON;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; RATING SCALE;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NAUSEA; TRANSPLANTATION, HOMOLOGOUS; VOMITING;

EID: 80053962348     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant 2008; 42: 501-506.
2. de Boer-Dennert M, de Wit R, Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997; 76: 1055-1061. (Pubitemid 27434663)
3. Coates AS, Abraham S, Kaye SB. On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208. (Pubitemid 13155858)
4. Griffin AM, Butow PN, Coates AS. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
5. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000; 20: 113-121.
6. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003; 21: 4077-4080. (Pubitemid 46606172)
7. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004; 12: 708-715. (Pubitemid 39362649)
8. Lindley CM, Hirsch JD, O'Neill CV. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-340.
9. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790-1796.
10. Hesketh PJ, Gandata DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613-620.
11. Strum SB, McDermed JE, Pileggi J, Riech LP, Whitaker H. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting: a preliminary evaluation. Cancer 1984; 53: 1432-1439. (Pubitemid 14198909)
12. Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986; 70: 555-563. (Pubitemid 16120999)
13. Jordan NS, Schauer PK, Schauer A et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985; 3: 559-561. (Pubitemid 15111405)
14. Jones R, Nieto Y, Rizzo JD et al. The evolution of the evident-based review: evaluating the science enhances the art of medicine - statement of the steering committee for evidence-based reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2005; 11: 819-822. (Pubitemid 41645638)
15. Kris MG, Tomnato M, Bra E et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic risk chemotherapy. Support Care Cancer 2010; DOI: 10.1007/s00520-010-0976-9.
16. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947. (Pubitemid 46630595)
17. Jordan K, Kinitz I, Voigt W et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45: 1184-1187.
18. Paul B, Travato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic cell support. J Oncol Pharm Practice 2010; 16: 45-51.
19. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8: 33-39. (Pubitemid 30096543)
20. Sarcev T, Secen N, Zaric B, Milovancev A. Aprepitant-where do we stand in the control of chemotherapy-induced nausea and vomiting? J BUON 2008; 13: 333-339.
21. Sarcev T, Secen N, Povazan Dj, et al. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting. J BUON 2007; 12: 245-252. (Pubitemid 47034436)
22. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69: 515-533.
23. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 2009; 10: 629-644.
24. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577. (Pubitemid 37304615)
25. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
26. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449. (Pubitemid 44400384)
27. Botrel TE, Clark OA, Clark L et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT(3)R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 2010; DOI: 10.1007/s00520-010-0908-8.
28. Longo F, Mansueto G, Lapadula V et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2010; DOI: 10.1007/s00520-010-0930- x.
29. Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835-842.
30. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002; 94: 3032-3041. (Pubitemid 34547705)
31. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-1767. (Pubitemid 32230878)
32. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-2300. (Pubitemid 36444075)
33. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340: 190-195.
34. Bubalo JS, Leis JF, Curin PT et al. A double blinded pilot study of aprepitant vs placebo combined with standard antiemetics for the control of nausea and vomiting during hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13 (Suppl): 152 (abstr).
35. Bubalo JS, Lets JF, Curtin PT et al. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007; 25 (18S): 9112 (abstr).
36. Navari RM, Einhorn LH, Passik SD et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 2005; 13: 529-534. (Pubitemid 40933610)
37. Rudd JA, Ngan MP, Wai MK et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 2006; 392: 79-83. (Pubitemid 41757580)
38. Tremblay PB, Kaiser R, Sezer O et al. Variations in the 5-HT3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147-2155. (Pubitemid 46606363)